Augmenting the Treatment of PTSD with Ketamine—a Review
- 37 Downloads
Posttraumatic stress disorder (PTSD) is a debilitating psychiatric disorder with a lifetime prevalence of 6.1% in the general adult population. Clinical guidelines for the treatment of PTSD suggest the use of trauma-focused psychotherapies such as prolonged exposure (PE) and cognitive-behavioral therapy (CBT). As a second-level intervention, these guidelines suggest the use of psychotropic medications, mainly selective serotonin reuptake inhibitors (SSRIs). To date, however, studies have shown that both psychotherapeutic and psychopharmacologic treatments have limited efficacy, with remission rates around 40–70% and dropout rates of up to 50%. This paper reviews a new and emerging treatment approach of medication-augmented psychotherapy for PTSD, with an emphasis on augmenting prolonged exposure therapy (PE) with sub-anesthetic ketamine infusion. Based on animal and human research on fear extinction and memory reconsolidation, neurobiological changes that emerge following a ketamine infusion can enhance learning and thus benefit exposure-based psychotherapies for PTSD.
Medication-augmented exposure-based psychotherapies represent a promising direction for the treatment of PTSD, with some positive results in small-scale studies. More studies (phase 2 and 3) should be performed to determine if this multimodal treatment approach may help mitigate PTSD symptoms in trauma-exposed individuals who do not respond to standard monotherapeutic approaches.
KeywordsPTSD Ketamine Prolonged exposure Augmenting psychotherapy MDMA DCS
Compliance with Ethical Standards
Conflict of Interest
Or Duek declares that he has no conflict of interest. Benjamin Kelmendi declares that he has no conflict of interest. Ilan Harpaz-Rotem declares that he has no conflict of interest. Robert H. Pietrzak is a scientific consultant with Cogstate and received payment from them.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 4.Goldstein RB, Smith SM, Chou SP, Saha TD, Jung J, Zhang H, et al. The epidemiology of DSM-5 posttraumatic stress disorder in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions-III. Soc Psychiatry Psychiatr Epidemiol. 2016;51:1137–48. https://doi.org/10.1007/s00127-016-1208-5.CrossRefGoogle Scholar
- 5.Seal KH, Bertenthal D, Miner CR, Sen S, Marmar C. Bringing the war back home: mental health disorders among 103 788 US veterans returning from Iraq and Afghanistan seen at Department of Veterans Affairs Facilities. Arch Intern Med Am Med Assoc. 2007;167:476–82. https://doi.org/10.1001/archinte.167.5.476.CrossRefGoogle Scholar
- 6.Smith SM, Goldstein RB, Grant BF. The association between post-traumatic stress disorder and lifetime DSM-5 psychiatric disorders among veterans: data from the National Epidemiologic Survey on Alcohol and Related Conditions-III (NESARC-III). J Psychiatr Res. 2016;82:16–22. https://doi.org/10.1016/j.jpsychires.2016.06.022.CrossRefGoogle Scholar
- 7.Pietrzak RH, Goldstein RB, Southwick SM, Grant BF. Prevalence and Axis I comorbidity of full and partial posttraumatic stress disorder in the United States: results from Wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions. J Anxiety Disord. 2011;25:456–65. https://doi.org/10.1016/j.janxdis.2010.11.010.CrossRefGoogle Scholar
- 8.Schnurr PP, Hayes AF, Lunney CA, McFall M, Uddo M. Longitudinal analysis of the relationship between symptoms and quality of life in veterans treated for posttraumatic stress disorder. J Consult Clin Psychol. psycnet.apa.org. 2006;74:707–13. https://doi.org/10.1037/0022-006X.74.4.707.CrossRefGoogle Scholar
- 10.Marmar CR, Schlenger W, Henn-Haase C, Qian M, Purchia E, Li M, et al. Course of posttraumatic stress disorder 40 years after the Vietnam War: findings from the National Vietnam Veterans Longitudinal Study. JAMA Psychiatry. jamanetwork.com. 2015;72:875–81. https://doi.org/10.1001/jamapsychiatry.2015.0803.CrossRefGoogle Scholar
- 13.Committee on Treatment of Posttraumatic Stress Disorder, Board on Population Health and Public Health Practice, Institute of Medicine. Treatment of posttraumatic stress disorder: an assessment of the evidence. National Academies Press; 2008, DOI: https://doi.org/10.3768/rtipress.2008.mr.0007.0809.
- 14.Courtois CA, Sonis J, Fairbank JA, Friedman M, Jones R, Roberts J, et al. Clinical practice guideline for the treatment of posttraumatic stress disorder (PTSD) in adults. Manuscript submitted for publication. 2017, DOI: https://doi.org/10.1310/sci2301-20;
- 15.Monson CM, Shnaider P. Treating PTSD with cognitive-behavioral therapies: interventions that work. American Psychological Association; 2014, DOI: https://doi.org/10.3389/fpsyg.2014.01239.
- 16.Resick PA, Monson CM, Chard KM. Cognitive processing therapy for PTSD: a comprehensive manual. Guilford Publications; 2016.Google Scholar
- 17.Ehlers A, Hackmann A, Grey N, Wild J, Liness S, Albert I, et al. A randomized controlled trial of 7-day intensive and standard weekly cognitive therapy for PTSD and emotion-focused supportive therapy. Am J Psychiatry. 2014;171:294–304. https://doi.org/10.1176/appi.ajp.2013.13040552.CrossRefGoogle Scholar
- 20.• Kelmendi B, Adams TG, Yarnell S, Southwick S, Abdallah CG, Krystal JH. PTSD: from neurobiology to pharmacological treatments. Eur J Psychotraumatol. 2016;7:31858. This review paper provides details on mechanism of mechanism of action of pharmacological treatments for PTSD, including ketamine and MDMA. https://doi.org/10.3402/ejpt.v7.31858.CrossRefGoogle Scholar
- 21.Rauch SAM, Kim HM, Powell C, Tuerk PW, Simon NM, Acierno R, et al. Efficacy of prolonged exposure therapy, sertraline hydrochloride, and their combination among combat veterans with posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry [Internet]. 2018;76:117–26; Available from. https://doi.org/10.1001/jamapsychiatry.2018.3412.CrossRefGoogle Scholar
- 22.Berger W, Mendlowicz MV, Marques-Portella C, Kinrys G, Fontenelle LF, Marmar CR, et al. Pharmacologic alternatives to antidepressants in posttraumatic stress disorder: a systematic review. Prog Neuro-Psychopharmacol Biol Psychiatry. 2009;33:169–80. https://doi.org/10.1016/j.pnpbp.2008.12.004.CrossRefGoogle Scholar
- 26.National Collaborating Centre for Mental Health (UK). Common mental health disorders: identification and pathways to care. Leicester (UK): British Psychological Society; 2012.Google Scholar
- 28.Shapiro F Eye movement desensitization and reprocessing (EMDR) therapy, 3rd Edition: Basic Principles, Protocols, and Procedures. Guilford Publications; 2017, DOI: https://doi.org/10.1103/PhysRevD.95.101303.
- 30.Schauer M, Schauer M, Neuner F, Elbert T. Narrative exposure therapy: a short-term treatment for traumatic stress disorders. Hogrefe Publishing; 2011.Google Scholar
- 35.Chambers RA, Bremner JD, Moghaddam B, Southwick SM, Charney DS, Krystal JH. Glutamate and post-traumatic stress disorder: toward a psychobiology of dissociation. Semin Clin Neuropsychiatry. 1999;4:274–81. https://doi.org/10.153/SCNP00400274.Google Scholar
- 38.Vyas A, Pillai AG, Chattarji S. Recovery after chronic stress fails to reverse amygdaloid neuronal hypertrophy and enhanced anxiety-like behavior. Neuroscience. 2004;128:667–73. https://doi.org/10.1016/j.neuroscience.2004.07.013.CrossRefGoogle Scholar
- 41.• Clarke M, Razmjou S, Prowse N, Dwyer Z, Litteljohn D, Pentz R, et al. Ketamine modulates hippocampal neurogenesis and pro-inflammatory cytokines but not stressor induced neurochemical changes. Neuropharmacology. 2017;112:210–20. This paper provides an in depths explanation of the mechanism behind ketamine and neurogenesis. https://doi.org/10.1016/j.neuropharm.2016.04.021.CrossRefGoogle Scholar
- 42.Bai X, Yan Y, Canfield S, Muravyeva MY, Kikuchi C, Zaja I, et al. Ketamine enhances human neural stem cell proliferation and induces neuronal apoptosis via reactive oxygen species-mediated mitochondrial pathway. Anesth Analg. 2013;116:869–80. https://doi.org/10.1213/ANE.0b013e3182860fc9.CrossRefGoogle Scholar
- 44.Smith NB, Doran JM, Sippel LM, Harpaz-Rotem I. Fear extinction and memory reconsolidation as critical components in behavioral treatment for posttraumatic stress disorder and potential augmentation of these processes. Neurosci Lett. 2017;649:170–5. https://doi.org/10.1016/j.neulet.2017.01.006.CrossRefGoogle Scholar
- 46.Garfinkel SN, Abelson JL, King AP, Sripada RK, Wang X, Gaines LM, et al. Impaired contextual modulation of memories in PTSD: an fMRI and psychophysiological study of extinction retention and fear renewal. J Neurosci. 2014;34:13435–43. https://doi.org/10.1523/JNEUROSCI.4287-13.2014.CrossRefGoogle Scholar
- 53.Rothbaum BO, Price M, Jovanovic T, Norrholm SD, Gerardi M, Dunlop B, et al. A randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy for posttraumatic stress disorder in Iraq and Afghanistan War veterans. Am J Psychiatry. 2014;171:640–8. https://doi.org/10.1176/appi.ajp.2014.13121625.CrossRefGoogle Scholar
- 60.Duclot F, Perez-Taboada I, Wright KN, Kabbaj M. Prediction of individual differences in fear response by novelty seeking, and disruption of contextual fear memory reconsolidation by ketamine. Neuropharmacology. 2016;109:293–305. https://doi.org/10.1016/j.neuropharm.2016.06.022.CrossRefGoogle Scholar
- 66.Albott CS, Lim KO, Forbes MK, Erbes C, Tye SJ, Grabowski JG, et al. Efficacy, safety, and durability of repeated ketamine infusions for comorbid posttraumatic stress disorder and treatment-resistant depression. J Clin Psychiatry [Internet]. 2018;79:17m11634. Available from. https://doi.org/10.4088/JCP.17m11634.Google Scholar
- 67.Weathers FW, Litz BT, Keane TM, Palmieri PA, Marx BP, Schnurr PP. The ptsd checklist for dsm-5 (pcl-5). Scale available from the National Center for PTSD at www ptsd va gov 2013, DOI: https://doi.org/10.1055/s-0033-1351234;
- 69.Pradhan B, Mitrev L, Moaddell R, Wainer IW. d-Serine is a potential biomarker for clinical response in treatment of post-traumatic stress disorder using (R,S)-ketamine infusion and TIMBER psychotherapy: a pilot study. Biochim Biophys Acta, Proteins Proteomics. 2018;1866:831–9. https://doi.org/10.1016/j.bbapap.2018.03.006.CrossRefGoogle Scholar
- 70.Zimmerman JM, Maren S. NMDA receptor antagonism in the basolateral but not central amygdala blocks the extinction of Pavlovian fear conditioning in rats: central amygdala, glutamate receptors and extinction of fear. Eur J Neurosci. 2010;17:no, DOI: https://doi.org/10.1111/j.1460-9568.2010.07223.x.